Altimmune, Inc. (NASDAQ:ALT) Given Consensus Rating of “Moderate Buy” by Brokerages

Altimmune, Inc. (NASDAQ:ALT) has received an average recommendation of “Moderate Buy” from the ten ratings firms that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $16.8333.

ALT has been the topic of a number of recent research reports. Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a report on Wednesday, November 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a research report on Monday, December 22nd. Citizens Jmp decreased their price target on Altimmune from $15.00 to $14.00 and set a “market outperform” rating on the stock in a research note on Friday, November 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research note on Monday, October 20th.

Insider Activity

In other news, Director John Gill purchased 12,500 shares of Altimmune stock in a transaction on Tuesday, December 23rd. The shares were purchased at an average cost of $4.10 per share, for a total transaction of $51,250.00. Following the completion of the transaction, the director directly owned 12,500 shares in the company, valued at approximately $51,250. This represents a ? increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jerome Benedict Durso acquired 12,500 shares of the firm’s stock in a transaction on Monday, December 22nd. The shares were purchased at an average cost of $4.13 per share, for a total transaction of $51,625.00. Following the completion of the purchase, the director directly owned 12,500 shares of the company’s stock, valued at approximately $51,625. The trade was a ? increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders bought 25,527 shares of company stock worth $104,878. 4.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Geneos Wealth Management Inc. bought a new stake in Altimmune during the 1st quarter worth approximately $50,000. Victory Capital Management Inc. bought a new position in Altimmune in the 3rd quarter valued at $38,000. BNP Paribas Financial Markets boosted its stake in Altimmune by 108.5% in the second quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company’s stock worth $39,000 after purchasing an additional 5,253 shares in the last quarter. Kingswood Wealth Advisors LLC bought a new stake in shares of Altimmune during the second quarter worth $40,000. Finally, Prudential Financial Inc. bought a new stake in shares of Altimmune during the second quarter worth $43,000. 78.05% of the stock is owned by institutional investors and hedge funds.

Altimmune Trading Down 4.7%

Shares of ALT stock opened at $3.68 on Tuesday. The firm has a fifty day moving average of $4.51 and a 200-day moving average of $4.30. The stock has a market cap of $383.97 million, a price-to-earnings ratio of -3.44 and a beta of -0.03. Altimmune has a 52-week low of $2.90 and a 52-week high of $7.83. The company has a debt-to-equity ratio of 0.08, a quick ratio of 17.18 and a current ratio of 17.18.

Altimmune (NASDAQ:ALT) last issued its earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.08. Altimmune had a negative net margin of 419,575.00% and a negative return on equity of 54.79%. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. On average, equities research analysts forecast that Altimmune will post -1.35 earnings per share for the current fiscal year.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.